PTEN is altered in 8.13% of malignant solid tumor patients with PTEN Loss present in 1.89% of all malignant solid tumor patients [4].

PTEN Loss is an inclusion criterion in 46 clinical trials for malignant solid tumor, of which 34 are open and 12 are closed. Of the trials that contain PTEN Loss and malignant solid tumor as inclusion criteria, 19 are phase 1 (11 open), 11 are phase 1/phase 2 (8 open), 15 are phase 2 (14 open), and 1 is phase 4 (1 open) [5].

PTEN is altered in 7.35% of breast carcinoma patients with PTEN Loss present in 1.61% of all breast carcinoma patients [4].

PTEN Loss is an inclusion criterion in 29 clinical trials for breast carcinoma, of which 23 are open and 6 are closed. Of the trials that contain PTEN Loss and breast carcinoma as inclusion criteria, 8 are phase 1 (5 open), 6 are phase 1/phase 2 (4 open), 12 are phase 2 (11 open), and 3 are phase 3 (3 open) [5].

PTEN is altered in 17.77% of prostate carcinoma patients with PTEN Loss present in 11.6% of all prostate carcinoma patients [4].

PTEN Loss is an inclusion criterion in 15 clinical trials for prostate carcinoma, of which 9 are open and 6 are closed. Of the trials that contain PTEN Loss and prostate carcinoma as inclusion criteria, 5 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [5].

PTEN is altered in 4.06% of ovarian carcinoma patients with PTEN Loss present in 1.22% of all ovarian carcinoma patients [4].

PTEN Loss is an inclusion criterion in 12 clinical trials for ovarian carcinoma, of which 7 are open and 5 are closed. Of the trials that contain PTEN Loss and ovarian carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [5].

PTEN is altered in 3.33% of non-small cell lung carcinoma patients with PTEN Loss present in 0.51% of all non-small cell lung carcinoma patients [4].

PTEN Loss is an inclusion criterion in 12 clinical trials for non-small cell lung carcinoma, of which 6 are open and 6 are closed. Of the trials that contain PTEN Loss and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 6 are phase 1/phase 2 (3 open), and 4 are phase 2 (3 open) [5].

PTEN is altered in 17.72% of prostate adenocarcinoma patients with PTEN Loss present in 11.46% of all prostate adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain PTEN Loss and prostate adenocarcinoma as inclusion criteria, 9 are phase 2 (8 open) and 1 is phase 3 (1 open) [5].

PTEN is altered in 4.89% of medulloblastoma patients with PTEN Loss present in 1.14% of all medulloblastoma patients [4].

PTEN Loss is an inclusion criterion in 9 clinical trials for medulloblastoma, of which 9 are open and 0 are closed. Of the trials that contain PTEN Loss and medulloblastoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [5].

PTEN is altered in 48.03% of endometrial carcinoma patients with PTEN Loss present in 0.24% of all endometrial carcinoma patients [4].

PTEN Loss is an inclusion criterion in 8 clinical trials for endometrial carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PTEN Loss and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

PTEN is altered in 10.72% of small cell lung carcinoma patients with PTEN Loss present in 3.66% of all small cell lung carcinoma patients [4].

PTEN Loss is an inclusion criterion in 7 clinical trials for small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [5].

PTEN is altered in 6.31% of head and neck squamous cell carcinoma patients with PTEN Loss present in 1.54% of all head and neck squamous cell carcinoma patients [4].

PTEN Loss is an inclusion criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 4 are closed. Of the trials that contain PTEN Loss and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [5].

PTEN is altered in 8.17% of melanoma patients with PTEN Loss present in 2.39% of all melanoma patients [4].

PTEN Loss is an inclusion criterion in 6 clinical trials for melanoma, of which 4 are open and 2 are closed. Of the trials that contain PTEN Loss and melanoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].

PTEN is altered in 6.26% of colorectal carcinoma patients with PTEN Loss present in 1.44% of all colorectal carcinoma patients [4].

PTEN Loss is an inclusion criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN Loss and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].

PTEN is altered in 8.7% of primary peritoneal carcinoma patients [4].

PTEN Loss is an inclusion criterion in 6 clinical trials for primary peritoneal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN Loss and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [5].

PTEN is altered in 9.73% of squamous cell lung carcinoma patients with PTEN Loss present in 1.55% of all squamous cell lung carcinoma patients [4].

PTEN Loss is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN Loss and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (1 open) [5].

PTEN is altered in 1.59% of fallopian tube carcinoma patients [4].

PTEN Loss is an inclusion criterion in 5 clinical trials for fallopian tube carcinoma, of which 2 are open and 3 are closed. Of the trials that contain PTEN Loss and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [5].

PTEN is altered in 3.05% of non-hodgkin lymphoma patients with PTEN Loss present in 1.63% of all non-hodgkin lymphoma patients [4].

PTEN Loss is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

PTEN is altered in 4.16% of adenocarcinoma of the gastroesophageal junction patients with PTEN Loss present in 1.0% of all adenocarcinoma of the gastroesophageal junction patients [4].

PTEN Loss is an inclusion criterion in 4 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 1 is closed. Of the trials that contain PTEN Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [5].

PTEN is altered in 4.24% of gastric carcinoma patients with PTEN Loss present in 0.93% of all gastric carcinoma patients [4].

PTEN Loss is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Loss and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [5].

PTEN is altered in 3.71% of urothelial carcinoma patients with PTEN Loss present in 0.59% of all urothelial carcinoma patients [4].

PTEN Loss is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Loss and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PTEN is altered in 1.1% of pancreatic adenocarcinoma patients with PTEN Loss present in 0.21% of all pancreatic adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

PTEN Loss is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain PTEN Loss and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

PTEN is altered in 37.66% of glioblastoma patients with PTEN Loss present in 7.24% of all glioblastoma patients [4].

PTEN Loss is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN Loss and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

PTEN is altered in 3.82% of osteosarcoma patients with PTEN Loss present in 3.49% of all osteosarcoma patients [4].

PTEN Loss is an inclusion criterion in 3 clinical trials for osteosarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN Loss and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PTEN is altered in 4.51% of soft tissue sarcoma patients with PTEN Loss present in 2.15% of all soft tissue sarcoma patients [4].

PTEN Loss is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PTEN is altered in 4.28% of gastric adenocarcinoma patients with PTEN Loss present in 0.94% of all gastric adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [5].

PTEN is altered in 9.75% of leiomyosarcoma patients with PTEN Loss present in 7.51% of all leiomyosarcoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and leiomyosarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PTEN is altered in 29.52% of malignant glioma patients with PTEN Loss present in 5.78% of all malignant glioma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [5].

PTEN is altered in 6.38% of undifferentiated pleomorphic sarcoma patients with PTEN Loss present in 3.24% of all undifferentiated pleomorphic sarcoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for undifferentiated pleomorphic sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 2.65% of chondrosarcoma patients with PTEN Loss present in 1.82% of all chondrosarcoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 7.58% of cancer patients with PTEN Loss present in 1.8% of all cancer patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain PTEN Loss and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 1 (1 open) [5].

PTEN is altered in 3.02% of hepatocellular carcinoma patients with PTEN Loss present in 1.79% of all hepatocellular carcinoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 1.54% of Ewing sarcoma patients with PTEN Loss present in 1.49% of all Ewing sarcoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 5.25% of head and neck carcinoma patients with PTEN Loss present in 1.15% of all head and neck carcinoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 3.53% of central nervous system embryonal neoplasm patients with PTEN Loss present in 0.79% of all central nervous system embryonal neoplasm patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

PTEN is altered in 2.48% of esophageal carcinoma patients with PTEN Loss present in 0.74% of all esophageal carcinoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PTEN is altered in 3.12% of gastrointestinal stromal tumor patients with PTEN Loss present in 0.74% of all gastrointestinal stromal tumor patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 5.57% of clear cell renal cell carcinoma patients with PTEN Loss present in 0.28% of all clear cell renal cell carcinoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 5.65% of renal cell carcinoma patients with PTEN Loss present in 0.23% of all renal cell carcinoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PTEN is altered in 1.11% of pancreatic carcinoma patients with PTEN Loss present in 0.2% of all pancreatic carcinoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN is altered in 0.31% of myeloid neoplasm patients with PTEN Loss present in 0.04% of all myeloid neoplasm patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

PTEN is altered in 5.0% of desmoplastic/nodular medulloblastoma patients [4].

PTEN Loss is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Loss and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

PTEN is altered in 16.67% of pleomorphic rhabdomyosarcoma patients with PTEN Loss present in 9.09% of all pleomorphic rhabdomyosarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 8.57% of pancreatic ductal adenocarcinoma patients with PTEN Loss present in 6.67% of all pancreatic ductal adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTEN Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

PTEN is altered in 26.87% of diffuse glioma patients with PTEN Loss present in 5.14% of all diffuse glioma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 21.97% of glioma patients with PTEN Loss present in 4.23% of all glioma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 20.51% of malignant central nervous system neoplasm patients with PTEN Loss present in 4.0% of all malignant central nervous system neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 13.86% of high-grade glioma, NOS patients with PTEN Loss present in 3.85% of all high-grade glioma, NOS patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 7.5% of pleomorphic liposarcoma patients with PTEN Loss present in 2.7% of all pleomorphic liposarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 4.26% of malignant peripheral nerve sheath tumor patients with PTEN Loss present in 2.41% of all malignant peripheral nerve sheath tumor patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 4.41% of rhabdomyosarcoma patients with PTEN Loss present in 1.8% of all rhabdomyosarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 8.99% of oropharyngeal squamous cell carcinoma patients with PTEN Loss present in 1.69% of all oropharyngeal squamous cell carcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 1.96% of thymic carcinoma patients with PTEN Loss present in 1.69% of all thymic carcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 7.11% of breast adenocarcinoma patients with PTEN Loss present in 1.53% of all breast adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

PTEN is altered in 7.3% of cervical carcinoma patients with PTEN Loss present in 1.5% of all cervical carcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 2.99% of B-cell non-hodgkin lymphoma patients with PTEN Loss present in 1.43% of all B-cell non-hodgkin lymphoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 6.22% of malignant intestinal neoplasm patients with PTEN Loss present in 1.42% of all malignant intestinal neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 6.23% of colorectal adenocarcinoma patients with PTEN Loss present in 1.4% of all colorectal adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 2.71% of high grade ovarian serous adenocarcinoma patients with PTEN Loss present in 1.38% of all high grade ovarian serous adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 4.51% of malignant ovarian epithelial tumor patients with PTEN Loss present in 1.18% of all malignant ovarian epithelial tumor patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 3.74% of malignant mesothelioma patients with PTEN Loss present in 1.12% of all malignant mesothelioma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 8.58% of anaplastic astrocytoma patients with PTEN Loss present in 1.09% of all anaplastic astrocytoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 4.86% of malignant small intestinal neoplasm patients with PTEN Loss present in 0.98% of all malignant small intestinal neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 1.53% of follicular lymphoma patients with PTEN Loss present in 0.94% of all follicular lymphoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 2.02% of hematologic and lymphocytic disorder patients with PTEN Loss present in 0.94% of all hematologic and lymphocytic disorder patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 4.24% of malignant gastric neoplasm patients with PTEN Loss present in 0.93% of all malignant gastric neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 2.56% of esophageal adenocarcinoma patients with PTEN Loss present in 0.9% of all esophageal adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 3.29% of malignant esophagogastric neoplasm patients with PTEN Loss present in 0.79% of all malignant esophagogastric neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 4.18% of liposarcoma patients with PTEN Loss present in 0.7% of all liposarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 2.14% of ampulla of vater carcinoma patients with PTEN Loss present in 0.69% of all ampulla of vater carcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 2.58% of biliary tract carcinoma patients with PTEN Loss present in 0.66% of all biliary tract carcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 1.07% of hematopoietic and lymphoid malignancy patients with PTEN Loss present in 0.63% of all hematopoietic and lymphoid malignancy patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 0.53% of neuroblastoma patients with PTEN Loss present in 0.59% of all neuroblastoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 1.05% of hematopoietic and lymphoid system neoplasm patients with PTEN Loss present in 0.53% of all hematopoietic and lymphoid system neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 1.96% of bile duct adenocarcinoma patients with PTEN Loss present in 0.24% of all bile duct adenocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 1.96% of cholangiocarcinoma patients with PTEN Loss present in 0.24% of all cholangiocarcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 4.59% of thyroid gland carcinoma patients with PTEN Loss present in 0.09% of all thyroid gland carcinoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 0.24% of acute myeloid leukemia patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 3.17% of anaplastic ependymoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 2.22% of anaplastic oligodendroglioma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 2.48% of angiosarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for bannayan syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and bannayan syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 14.29% of breast lobular carcinoma in situ patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for cowden syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and cowden syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for extraskeletal osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and extraskeletal osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

PTEN is altered in 0.74% of histiocytic and dendritic cell neoplasm patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 0.11% of myelodysplastic syndromes patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN is altered in 4.55% of myxofibrosarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN is altered in 16.9% of myxoid liposarcoma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and myxoid liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN is altered in 1.08% of peritoneal mesothelioma patients [4].

PTEN Loss is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for proteus syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and proteus syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Loss is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PTEN Loss and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [5].